Skip to content

Information for students, faculty and staff regarding COVID-19. (Updated: 11 May 2021)

printicon

Artificial intelligence in oncology: European REVERT

Research project REVERT, is a EU Horizon 2020 funded project aiming to apply artificial intelligence to develop predictive algorithms to be used in clinical treatment of patients with advanced colorectal cancer.

Personalised medicine model for the treatment of advanced colorectal cancer.

Head of project

Project overview

Project period:

2020-01-01 2023-12-31

Participating departments and units at Umeå University

Department of Molecular Biology

Research area

Cancer, Clinical medicine, Computing science, Molecular medicine

Project description

The EU-funded REVERT project will address at systems level the pathophysiology of advanced colorectal cancer in patients responding well or poorly to therapies, with the goal to design an optimal strategy for therapeutic interventions depending on patients' features. This goal will be achieved using a large number of standardised biobank samples and clinical databases from several clinical European centres, including known and new potential prognostic biomarkers. Following the AI-based data analysis, results will be evaluated for the REVERT-DataBase impact on survival and quality of life in prospective clinical trials. The project will also generate a broad network among industrial and academic partners focused on the development of personalised medicine.

https://cordis.europa.eu/project/id/848098
EU Horizon 2020

Systems approaches for the discovery of combinatorial therapies for complex disorders.

Project Information

REVERT
Grant agreement ID: 848098
Status: Ongoing project
Start date: 1 January 2020
End date: 31 December 2023
Funded under: H2020-EU.3.1.1.
Overall budget: € 5 887 273,75